Abstract:Fragile X syndrome (FXS) is the most common genetic cause of intellectual disability and the most common single-gene cause of autism. It is caused by mutations on the fragile X mental retardation gene (FMR1) and lack of fragile X mental retardation protein, which in turn, leads to decreased inhibition of translation of many synaptic proteins. The metabotropic glutamate receptor (mGluR) hypothesis states that the neurological deficits in individuals with FXS are due mainly to downstream consequences of overstimulation of the mGluR pathway. The main efforts have focused on mGluR5 targeted treatments; however, investigation on the gamma-aminobutyric acid (GABA) system and its potential as a targeted treatment is less emphasized. The fragile X mouse models (Fmr1-knock out) show decreased GABA subunit receptors, decreased synthesis of GABA, increased catabolism of GABA, and overall decreased GABAergic input in many regions of the brain. Consequences of the reduced GABAergic input in FXS include oversensitivity to sensory stimuli, seizures, and anxiety. Deficits in the GABA receptors in different regions of the brain are associated with behavioral and attentional processing deficits linked to anxiety and autistic behaviors. The understanding of the neurobiology of FXS has led to the development of targeted treatments for the core behavioral features of FXS, which include social deficits, inattention, and anxiety. These symptoms are also observed in individuals with autism and other neurodevelopmental disorders, therefore the targeted treatments for FXS are leading the way in the treatment of other neurodevelopmental syndromes and autism. The GABAergic system in FXS represents a target for new treatments. Herein, we discuss the animal and human trials of GABAergic treatment in FXS. Arbaclofen and ganaxolone have been used in individuals with FXS. Other potential GABAergic treatments, such as riluzole, gaboxadol, tiagabine, and vigabatrin, will be also discussed. Further studies are needed to determine the safety and efficacy of GABAergic treatments for FXS.

Impaired GABA Neural Circuits Are Critical for Fragile X Syndrome

Increased Coupling Of Caveolin-1 And Estrogen Receptor Alpha Contributes To The Fragile X Syndrome

Potential Pharmacological Treatment of Fragile X Syndrome During Adulthood

Imbalance between Glutamate and GABA in Fmr1 Knockout Astrocytes Influences Neuronal Development

Developmental Impairments of Synaptic Refinement in the Thalamus of a Mouse Model of Fragile X Syndrome

Maturation Delay of Human GABAergic Neurogenesis in Fragile X Syndrome Pluripotent Stem Cells

Epigenetic insights into Fragile X Syndrome

Modulation of the GABAergic pathway for the treatment of fragile X syndrome

Modeling Fragile X Syndrome: Characterizing Fmr1 Gene Knockout Mice across Genotype, Behavior, and Morphology

Hyperexcitability and Homeostasis in Fragile X Syndrome

Cell- and Pathway-Specific Disruptions in the Accumbens of Fragile X Mouse

Regulation of GABAA Receptors by Fragile X Mental Retardation Protein.

Caveolin-1-Mediated Cholesterol Accumulation Contributes to Exaggerated Mglur-Dependent Long-Term Depression and Impaired Cognition in Fmr1 Knockout Mice.

Fragile X Mental Retardation Protein is Required for Chemically‐induced Long‐term Potentiation of the Hippocampus in Adult Mice

New perspectives on the biology of fragile X syndrome.

A resting EEG study of neocortical hyperexcitability and altered functional connectivity in fragile X syndrome

Astrocytes regulate inhibition in Fragile X Syndrome

Thalamocortical dysrhythmia as a unifying model of neuropsychiatric and neurosensory dysfunction in fragile x syndrome

Fmr1 Deficiency Promotes Age-Dependent Alterations In The Cortical Synaptic Proteome

Enhanced Endocannabinoid Signaling Elevates Neuronal Excitability In Fragile X Syndrome

Identification of a molecular locus for normalizing dysregulated GABA release from interneurons in the Fragile X brain